Effexor Xr is a drug owned by Upjohn Us 2 Llc. It is protected by 11 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 20, 2017. Details of Effexor Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6419958 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(7 years ago) |
Expired
|
|
US6274171 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(7 years ago) |
Expired
|
|
US6403120 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep, 2017
(7 years ago) |
Expired
|
| US6403120 | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) |
Expired
|
| US6419958 | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) |
Expired
|
| US6274171 | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) |
Expired
|
|
US5916923 (Pediatric) | Venlafaxine for the treatment of generalized anxiety disorder |
Dec, 2013
(10 years ago) |
Expired
|
|
US6444708 (Pediatric) | Treatment using venlafaxine |
Dec, 2013
(10 years ago) |
Expired
|
| US5916923 | Venlafaxine for the treatment of generalized anxiety disorder |
Jun, 2013
(11 years ago) |
Expired
|
| US6310101 | Treatments using venlafaxine |
Jun, 2013
(11 years ago) |
Expired
|
| US6444708 | Treatment using venlafaxine |
Jun, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Effexor Xr's patents.
Latest Legal Activities on Effexor Xr's Patents
Given below is the list of recent legal activities going on the following patents of Effexor Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 26 Sep, 2014 | US6444708 |
| Correspondence Address Change Critical | 02 Sep, 2014 | US6444708 |
| Recordation of Patent Grant Mailed Critical | 03 Sep, 2002 | US6444708 |
| Patent Issue Date Used in PTA Calculation Critical | 03 Sep, 2002 | US6444708 |
| Issue Notification Mailed Critical | 15 Aug, 2002 | US6444708 |
| Receipt into Pubs | 06 Aug, 2002 | US6444708 |
| Application Is Considered Ready for Issue Critical | 01 Aug, 2002 | US6444708 |
| Recordation of Patent Grant Mailed Critical | 16 Jul, 2002 | US6419958 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Jul, 2002 | US6419958 |
| Receipt into Pubs | 15 Jul, 2002 | US6444708 |
US patents provide insights into the exclusivity only within the United States, but Effexor Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Effexor Xr's family patents as well as insights into ongoing legal events on those patents.
Effexor Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Effexor Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 20, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Effexor Xr Generic API suppliers:
Venlafaxine Hydrochloride is the generic name for the brand Effexor Xr. 39 different companies have already filed for the generic of Effexor Xr, with Cadila Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Effexor Xr's generic
How can I launch a generic of Effexor Xr before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Effexor Xr's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Effexor Xr's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Effexor Xr -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 37.5 mg, 75 mg and 150 mg | 03 May, 2007 | 1 | 20 Mar, 2017 | Extinguished |
Alternative Brands for Effexor Xr
Effexor Xr which is used for treating depression, generalized anxiety disorder, panic disorder, and social anxiety disorder., has several other brand drugs in the same treatment category and using the same active ingredient (Venlafaxine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Almatica |
| |||
| Osmotica Pharm Us |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Venlafaxine Hydrochloride, Effexor Xr's active ingredient. Check the complete list of approved generic manufacturers for Effexor Xr
About Effexor Xr
Effexor Xr is a drug owned by Upjohn Us 2 Llc. It is used for treating depression, generalized anxiety disorder, panic disorder, and social anxiety disorder. Effexor Xr uses Venlafaxine Hydrochloride as an active ingredient. Effexor Xr was launched by Upjohn in 1997.
Approval Date:
Effexor Xr was approved by FDA for market use on 20 October, 1997.
Active Ingredient:
Effexor Xr uses Venlafaxine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Venlafaxine Hydrochloride ingredient
Treatment:
Effexor Xr is used for treating depression, generalized anxiety disorder, panic disorder, and social anxiety disorder.
Dosage:
Effexor Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 75MG BASE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| EQ 150MG BASE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| EQ 100MG BASE | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| EQ 37.5MG BASE | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |